Compare ICCC & DCGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ICCC | DCGO |
|---|---|---|
| Founded | 1982 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Managed Health Care |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.8M | 71.0M |
| IPO Year | 1995 | 2020 |
| Metric | ICCC | DCGO |
|---|---|---|
| Price | $10.02 | $0.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.38 |
| AVG Volume (30 Days) | 28.0K | ★ 511.3K |
| Earning Date | 05-15-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 53.85 | N/A |
| EPS | ★ 0.21 | N/A |
| Revenue | $26,493,169.00 | ★ $322,196,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $6.77 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 51.64 | N/A |
| 52 Week Low | $4.52 | $0.49 |
| 52 Week High | $10.25 | $1.78 |
| Indicator | ICCC | DCGO |
|---|---|---|
| Relative Strength Index (RSI) | 73.69 | 51.87 |
| Support Level | $5.85 | $0.60 |
| Resistance Level | N/A | $0.87 |
| Average True Range (ATR) | 0.50 | 0.05 |
| MACD | 0.12 | -0.00 |
| Stochastic Oscillator | 97.37 | 59.62 |
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.
DocGo Inc is a provider of last-mile mobile health services and integrated medical mobility solutions. The company uses its care delivery platform to provide mobile health services, virtual care management, and ambulance services. It has two reporting segments: Mobile Health Services and Transportation Services. A majority of its revenue is generated from the Mobile Health Services segment, which includes various healthcare services performed at homes, offices, and other locations and event services such as on-site healthcare support at sporting events and concerts. Geographically, the company generates a majority of its revenue from the United States and the rest from the United Kingdom.